Patents by Inventor Brian Lichty
Brian Lichty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210128706Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: September 9, 2020Publication date: May 6, 2021Applicant: TURNSTONE LIMITED PARTNERSHIPInventors: David F. STOJDL, John Cameron BELL, Brian LICHTY, Jonathan POL
-
Patent number: 10925946Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.Type: GrantFiled: June 22, 2017Date of Patent: February 23, 2021Assignee: Turnstone Limited PartnershipInventors: Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
-
Patent number: 10660947Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: January 16, 2019Date of Patent: May 26, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: David F. Stojdl, John Cameron Bell, Brian Lichty
-
Patent number: 10646557Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: January 16, 2019Date of Patent: May 12, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: David F. Stojdl, John Cameron Bell, Brian Lichty
-
Publication number: 20190255160Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: January 16, 2019Publication date: August 22, 2019Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Publication number: 20190240301Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: January 16, 2019Publication date: August 8, 2019Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Patent number: 10363293Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: February 20, 2014Date of Patent: July 30, 2019Assignee: Turnstone Limited PartnershipInventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Publication number: 20190151437Abstract: A combination prime:boost therapy is described herein. The combination therapy is for use in inducing an immune response in a mammal. The combination includes: an adenovirus that is capable of expressing an antigenic protein, and that is formulated to generate an immunity to the protein in the mammal; and a Maraba MG1 virus that is capable of expressing an antigenic protein, and that is formulated to induce the immune response in the mammal. The antigenic proteins are both based on the same tumour associated antigen, but need not be identical. An adenovirus, methods of treatment, and uses are also described.Type: ApplicationFiled: May 9, 2017Publication date: May 23, 2019Inventors: Brian Lichty, Kyle Stephenson, Matthew Atherton
-
Publication number: 20190070280Abstract: The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) an oncolytic virus and (b) a checkpoint inhibitor and to its use for the treatment of cancer.Type: ApplicationFiled: August 9, 2018Publication date: March 7, 2019Inventors: BRIAN LICHTY, JOHN BELL
-
Publication number: 20190022203Abstract: The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) an oncolytic virus and (b) a checkpoint inhibitor and to its use for the treatment of cancer.Type: ApplicationFiled: January 11, 2017Publication date: January 24, 2019Inventors: Brian Lichty, John Bell
-
Publication number: 20180064805Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.Type: ApplicationFiled: October 16, 2017Publication date: March 8, 2018Inventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
-
Publication number: 20170348404Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.Type: ApplicationFiled: June 22, 2017Publication date: December 7, 2017Inventors: Brian Lichty, Bryam Bridle, Yonghong Wan, Jonathan Bramson
-
Patent number: 9821054Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.Type: GrantFiled: March 9, 2012Date of Patent: November 21, 2017Assignee: Turnstone Limited PartnershipInventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
-
Patent number: 9707285Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumor antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.Type: GrantFiled: March 16, 2010Date of Patent: July 18, 2017Assignee: Turnstone Limited PartnershipInventors: Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
-
Publication number: 20160106820Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: February 20, 2014Publication date: April 21, 2016Applicants: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC., OTTAWA HOSPITAL RESEARCH INSTITUTE, MCMASTER UNIVERSITYInventors: David F. STOJDL, John Cameron BELL, Brian LICHTY, Jonathan POL
-
Publication number: 20140193458Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.Type: ApplicationFiled: March 9, 2012Publication date: July 10, 2014Inventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
-
Publication number: 20120014990Abstract: In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune response in a mammal having a pre-existing immunity to an antigen is provided comprising intravenous administration to the mammal of a B-cell infecting vector that expresses the antigen.Type: ApplicationFiled: March 16, 2010Publication date: January 19, 2012Inventors: Brian Lichty, Byram Bridle, Yonghong Wan, Jonathan Bramson
-
Publication number: 20070166287Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picomavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: ApplicationFiled: March 13, 2007Publication date: July 19, 2007Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: John Bell, Nahum Sonenberg, David Stojdl, Earl Brown, Harold Atkins, Ricardo Marius, Brian Lichty, Shane Knowles
-
Publication number: 20070141033Abstract: The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.Type: ApplicationFiled: February 6, 2007Publication date: June 21, 2007Applicants: WELLSTAT BIOLOGICS CORPORATION, UNIVERSITY OF OTTAWAInventors: Harold Atkins, John Bell, Conrad Heilman, Brian Lichty, Robert Lorence, Michael Roberts, David Stojdl
-
Publication number: 20070098743Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: ApplicationFiled: March 29, 2004Publication date: May 3, 2007Inventors: John Bell, Brian Lichty, David Stodjl